Data-enriched edible pharmaceuticals (DEEP) of medical cannabis by inkjet printing
Research output: Contribution to journal › Journal article › peer-review
Standard
Data-enriched edible pharmaceuticals (DEEP) of medical cannabis by inkjet printing. / Öblom, Heidi; Cornett, Claus; Bøtker, Johan; Frokjaer, Sven; Hansen, Harald; Rades, Thomas; Rantanen, Jukka; Genina, Natalja.
In: International Journal of Pharmaceutics, Vol. 589, 119866, 2020, p. 1-11.Research output: Contribution to journal › Journal article › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Data-enriched edible pharmaceuticals (DEEP) of medical cannabis by inkjet printing
AU - Öblom, Heidi
AU - Cornett, Claus
AU - Bøtker, Johan
AU - Frokjaer, Sven
AU - Hansen, Harald
AU - Rades, Thomas
AU - Rantanen, Jukka
AU - Genina, Natalja
PY - 2020
Y1 - 2020
N2 - Medical cannabis has shown to be effective in various diseases that have not successfully been treated with other marketed drug products. However, the dose of cannabis is highly individual and additionally, medical cannabis is prone to misuse. To combat these challenges, the concept of data-enriched edible pharmaceuticals (DEEP) is introduced. Quick Response (QR) code patterns containing lipophilic cannabinoids, i.e., cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), were printed using a desktop inkjet printer. This allows for simultaneously printing an individual dose and encapsulating information relevant to the end-users and other stakeholders in a single dosage unit, which is readable by a standard smartphone. Different doses of CBD and THC were incorporated in the DEEP by printing various (1-10) layers of the cannabinoid-containing ink on porous substrates, i.e., solid foams, prepared by solvent casting and subsequent freeze-drying. The printed DEEP were still readable after 8 weeks of storage in dry and cold conditions. This approach of ‘in-drug labeling’ instead of ‘drug package labeling’ provides a new possibility for developing a more efficient supply chain of pharmaceuticals and safer medication schemes by increasing the traceability of drug products at a single dosage unit level.
AB - Medical cannabis has shown to be effective in various diseases that have not successfully been treated with other marketed drug products. However, the dose of cannabis is highly individual and additionally, medical cannabis is prone to misuse. To combat these challenges, the concept of data-enriched edible pharmaceuticals (DEEP) is introduced. Quick Response (QR) code patterns containing lipophilic cannabinoids, i.e., cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), were printed using a desktop inkjet printer. This allows for simultaneously printing an individual dose and encapsulating information relevant to the end-users and other stakeholders in a single dosage unit, which is readable by a standard smartphone. Different doses of CBD and THC were incorporated in the DEEP by printing various (1-10) layers of the cannabinoid-containing ink on porous substrates, i.e., solid foams, prepared by solvent casting and subsequent freeze-drying. The printed DEEP were still readable after 8 weeks of storage in dry and cold conditions. This approach of ‘in-drug labeling’ instead of ‘drug package labeling’ provides a new possibility for developing a more efficient supply chain of pharmaceuticals and safer medication schemes by increasing the traceability of drug products at a single dosage unit level.
KW - cannabinoids
KW - data
KW - inkjet printing
KW - misuse
KW - personalized medicine
KW - traceability
KW - QR code
U2 - 10.1016/j.ijpharm.2020.119866
DO - 10.1016/j.ijpharm.2020.119866
M3 - Tidsskriftartikel
C2 - 32919002
VL - 589
SP - 1
EP - 11
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
SN - 0378-5173
M1 - 119866
ER -
ID: 248289043